Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 0.7% – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares were down 0.7% during mid-day trading on Friday . The stock traded as low as GBX 572 and last traded at GBX 596. Approximately 985 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 60,595 shares. The stock had previously closed at GBX 600.

Hemogenyx Pharmaceuticals Stock Performance

The company’s fifty day simple moving average is GBX 747.37 and its two-hundred day simple moving average is GBX 595.98. The company has a market capitalization of £35.27 million, a price-to-earnings ratio of -2.58 and a beta of 3.14. The company has a debt-to-equity ratio of 90.87, a quick ratio of 6.72 and a current ratio of 4.38.

Hemogenyx Pharmaceuticals (LON:HEMO) last issued its earnings results on Tuesday, September 30th. The company reported GBX (0.83) earnings per share (EPS) for the quarter.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.